1997 May;99(6):1620-5. \[[PubMed: 9145132](https://pubmed.ncbi.nlm.nih.gov/9145132)\] 4. Cianci P, Lueders HW, Lee H, Shapiro RL, Sexton J, Williams C, Sato R. Adjunctive hyperbaric oxygen therapy reduces length of hospitalization in thermal burns. J Burn Care Rehabil. 1989 Sep-Oct;10(5):432-5. \[[PubMed: 2793923](https://pubmed.ncbi.nlm.nih.gov/2793923)\] 5. Villanueva E, Bennett MH, Wasiak J, Lehm JP. Hyperbaric oxygen therapy for thermal burns. Cochrane Database Syst Rev. 2004;2004(3):CD004727. \[[PMC free article: PMC8846294](/pmc/articles/PMC8846294/)\] \[[PubMed: 15266540](https://pubmed.ncbi.nlm.nih.gov/15266540)\] 6. Jones MW, Cooper JS. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 24, 2023. Hyperbaric Therapy for Skin Grafts and Flaps. \[[PubMed: 29262046](https://pubmed.ncbi.nlm.nih.gov/29262046)\] 7. Niinikoski JH. Clinical hyperbaric oxygen therapy, wound perfusion, and transcutaneous oximetry. World J Surg. 2004 Mar;28(3):307-11. \[[PubMed: 14961187](https://pubmed.ncbi.nlm.nih.gov/14961187)\] 8. Camporesi EM, Bosco G. Mechanisms of action of hyperbaric oxygen therapy. Undersea Hyperb Med. 2014 May-Jun;41(3):247-52. \[[PubMed: 24984320](https://pubmed.ncbi.nlm.nih.gov/24984320)\] 9. Leach RM, Rees PJ, Wilmshurst P. Hyperbaric oxygen therapy. BMJ. 1998 Oct 24;317(7166):1140-3. \[[PMC free article: PMC1114115](/pmc/articles/PMC1114115/)\] \[[PubMed: 9784458](https://pubmed.ncbi.nlm.nih.gov/9784458)\] 10. Hadanny A, Meir O, Bechor Y, Fishlev G, Bergan J, Efrati S. Seizures during hyperbaric oxygen therapy: retrospective analysis of 62,614 treatment sessions. Undersea Hyperb Med. 2016 Jan-Feb;43(1):21-8. \[[PubMed: 27000010](https://pubmed.ncbi.nlm.nih.gov/27000010)\] 11. Roth RN, Weiss LD. Hyperbaric oxygen and wound healing. Clin Dermatol. 1994 Jan-Mar;12(1):141-56. \[[PubMed: 8180937](https://pubmed.ncbi.nlm.nih.gov/8180937)\] **Disclosure:** Matthew Edwards declares no relevant financial relationships with ineligible companies. **Disclosure:** Jeffrey Cooper declares no relevant financial relationships with ineligible companies.